Trial Profile
Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet) + CARBOPLATIN IN EPITHELIAL ginecological CANCER [Estudio Fase I-II multicéntrico, abierto, de la combinación de doxorrubicina liposomal encapsulada (Myocet) y carboplatino en el tratamiento de pacientes con cáncer ginecológico o peritoneal primario recurrente].
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
- Indications Cervical cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2015 Results for the phase I portion in 23 evaluable patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 The phase I portion has been completed and the phase II portion is in progress, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 15 Jan 2013 New trial record